Skip to Content

Join the 'Acute Lymphoblastic Leukemia' group to help and get support from people like you.

Acute Lymphoblastic Leukemia News

Experimental Immune Cell Rx Shows Promise for Leukemia

Posted 21 Sep 2016 by

WEDNESDAY, Sept. 21, 2016 – An experimental therapy that revs up the immune system's cancer-fighting ability may help treat some leukemia patients who face a grim prognosis, a small study suggests. The treatment involves infusions of "natural killer" (NK) cells taken from a healthy donor and chemically "trained" to go after tumor cells. Researchers found that of nine patients with acute myeloid leukemia (AML) who received the therapy, four went into complete remission for as long as six months. The findings are preliminary, and the therapy remains experimental, the researchers pointed out. But experts said the results are encouraging considering the outlook these AML patients faced before the trial. Their cancer had either failed to respond to standard chemotherapy or had come back, and they had run out of options. "When you see this kind of response in these patients, it's ... Read more

Related support groups: Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Diagnosis and Investigation

FDA Approves Blincyto (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Posted 5 Sep 2016 by

THOUSAND OAKS, Calif., Sept. 1, 2016 /PRNewswire/ – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Blincyto (blinatumomab) to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of Blincyto in pediatric patients with relapsed or refractory B-cell precursor ALL. About Study '205 Study '205 evaluated the safety and efficacy of BLINCYTO in a Phase 1/2 ... Read more

Related support groups: Acute Lymphoblastic Leukemia, Blincyto, Blinatumomab

Exercise May Cut Risk of 13 Cancers, Study Suggests

Posted 16 May 2016 by

MONDAY, May 16, 2016 – Exercise may significantly reduce your risk for many types of cancer, including some of the most lethal forms of the disease, a large review suggests. Working out for even a couple of hours a week appears to shrink the risk of breast, colon and lung cancer, said researchers who looked at 1.4 million adults. "Those are three of the four major cancers that affect Americans today," said Marilie Gammon. She is a professor of epidemiology with the University of North Carolina at Chapel Hill Gillings School of Public Health. And fitness buffs, take heart – your cancer risk appears to continue to decline as you rack up hours of physical activity, with no apparent upper plateau, said study lead author Steven Moore, an investigator with the U.S. National Cancer Institute. "The more activity, the more the benefit," Moore said. "As people did more, their risk continued to ... Read more

Related support groups: Cancer, Breast Cancer, Leukemia, Lung Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Multiple Myeloma, Endometrial Cancer, Small Cell Lung Cancer, Acute Myeloid Leukemia, Bladder Cancer, Stomach Cancer, Head and Neck Cancer, Breast Cancer, Prevention, Acute Lymphoblastic Leukemia, Gastric Cancer, Osteolytic Bone Lesions of Multiple Myeloma, Urinary Tract Cancer, Acute Myeloblastic Leukemia

Certain Cancers Seem Less Likely for Kids of Hispanic Moms Born Outside U.S.

Posted 25 Apr 2016 by

MONDAY, April 25, 2016 – Children of Hispanic mothers who weren't born in the United States may be at lower risk for some types of childhood cancers, a new study suggests. "Incorporating the immigrant experience into studies of childhood cancer may help to inform research on disease [causes], identify vulnerable populations and highlight opportunities for cancer prevention," said Julia Heck, of the University of California, Los Angeles, and her study co-authors. It is important to evaluate childhood cancer risk in the large and growing Hispanic population, the research team said. For the study, the investigators analyzed data from children born in California between 1983 and 2012. The analysis was limited to children of U.S.-born white, U.S.-born Hispanic, or non-U.S.-born Hispanic mothers. Among the children, there were about 13,600 cancer diagnoses before age 6, and more than 15.5 ... Read more

Related support groups: Cancer, Acute Lymphoblastic Leukemia, Malignant Glioma, Neuroblastoma, Wilms' Tumor, Anaplastic Astrocytoma

New Immune Therapy Achieves Complete Remission in Blood Cancer Patients

Posted 16 Feb 2016 by

A new therapy that uses a person's immune system to attack tumors led to complete remission in terminally ill blood cancer patients, according to researchers. In a clinical trial, symptoms vanished in 94 percent of leukemia patients who received the treatment. The response rate was more than 80 percent in patients with other blood cancers, and half achieved total remission, CNBC reported. The results were presented Monday at the annual meeting of the American Association for the Advancement of Science. Detailed data will be published later this year. They therapy involves removing immune system T-cells from patients, loading them with anti-cancer molecules, and placing them back in the body. The altered T-cells then seek and destroy cancer, CNBC reported. The results are unprecedented, according to researcher Stanley Riddell. "In the laboratory and in clinical trials, we are seeing ... Read more

Related support groups: Blood Disorders, Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Diagnosis and Investigation, Chronic Eosinophilic Leukemia, Acute Nonlymphocytic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Meningeal Leukemia, Acute Myeloblastic Leukemia

Fewer Childhood Cancer Survivors Dying From 'Late' Effects

Posted 13 Jan 2016 by

WEDNESDAY, Jan. 13, 2016 – Fewer childhood cancer survivors are dying years later from lingering effects of the treatment that conquered their cancer, a new study finds. Experts called the report, published in the Jan. 14 issue of the New England Journal of Medicine, "very good news." "The findings substantiate what experts in the field have hoped would be true," said lead researcher Dr. Gregory Armstrong, of St. Jude Children's Research Hospital, in Memphis, Tenn. Survival rates from many childhood cancers are high, but survivors still face what doctors call "late effects" – health problems that develop months to years after the cancer treatment has ended. Among U.S. children who survived cancer back in the 1970s and '80s, 18 percent died within the next 25 years, Armstrong said. Sometimes, the initial cancer comes back. Often though, the health issues are related to the very ... Read more

Related support groups: Cancer, Methotrexate, Fluorouracil, Xeloda, Hydroxyurea, Mercaptopurine, Hydrea, Carboplatin, Cisplatin, Cytoxan, Dacogen, Bendamustine, Cyclophosphamide, Temodar, Oxaliplatin, Treanda, Gemzar, Capecitabine, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia

Antibody May Lower Rejection Rates After Stem Cell Transplant in Leukemia Patients

Posted 7 Jan 2016 by

WEDNESDAY, Jan. 6, 2016 – People with acute leukemia who were given antibody therapy before a stem cell transplant fared better than those who didn't receive the treatment, a small study found. Stem cell transplantation allows doctors to give higher doses of cancer-killing chemotherapy, according to the American Cancer Society. However, the odds of the body rejecting the transplanted stem cells are very high – a condition called graft-versus-host disease, the study authors explained. By treating patients first with animal-derived antibodies, called antihuman T-lymphocyte immune globulin (ATG), the researchers were able to lower the threat of rejection in patients. "Graft-versus-host disease is the most serious complication after stem cell transplantation," said lead researcher Dr. Francesca Bonifazi, from the Institute of Hematology at Bologna University in Italy. "Using [ATG] reduces ... Read more

Related support groups: Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Chronic Eosinophilic Leukemia, Acute Promyelocytic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Meningeal Leukemia, Acute Myeloblastic Leukemia

End-of-Life Talk Often Comes Too Late for Blood Cancer Patients

Posted 21 Dec 2015 by

MONDAY, Dec. 21, 2015 – Many doctors wait too long to have end-of-life discussions with blood cancer patients, a new study finds. Researchers analyzed surveys completed by 349 blood cancer specialists, and found that 56 percent said end-of-life discussions with patients happen too late. Nearly 43 percent said they had their first end-of-life discussions with patients at less-than-ideal times, the findings showed. About 23 percent of the doctors said they waited until death was imminent before discussing hospice care. And nearly 40 percent waited until death was imminent before they asked patients where they wanted to die. Several factors may contribute to the delay in end-of-life discussions with blood cancer patients, according to Dr. Oreofe Odejide, from the Dana-Farber Cancer Institute in Boston, and colleagues. While solid tumors are incurable after they reach an advanced stage, ... Read more

Related support groups: Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Nonlymphocytic Leukemia, Chronic Eosinophilic Leukemia, Infection Prophylaxis, Chronic Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia, Meningeal Leukemia

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Lymphoma, Basal Cell Carcinoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia, Burkitt Lymphoma

Jazz Pharmaceuticals Receives FDA Approval For Intravenous Administration Of Erwinaze

Posted 21 Dec 2014 by

DUBLIN, Dec. 19, 2014 /PRNewswire/ – Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase1. "Administration of Erwinaze through an intravenous infusion provides physicians another option for patients, including those who cannot tolerate intramuscular injections," said Jeffrey Tobias, M.D., executive vice president, research and development and chief medical officer of Jazz Pharmaceuticals plc. "Gaining FDA approval of this expanded label for Erwinaze reflects our continued commitment to improving patients' lives." Prior to this approval, the only ... Read more

Related support groups: Acute Lymphoblastic Leukemia, Asparaginase Erwinia Chrysanthemi, Erwinaze

FDA Approves Blincyto (blinatumomab) for Precursor B-Cell Acute Lymphoblastic Leukemia

Posted 3 Dec 2014 by

December 3, 2014 – The U.S. Food and Drug Administration today approved Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL. Precursor B-cell ALL is a rapidly growing type of cancer in which the bone marrow makes too many B-cell lymphoblasts, an immature type of white blood cell. The Philadelphia chromosome is an abnormality that sometimes occurs in the bone marrow cells of leukemia patients. The National Cancer Institute estimates that 6,020 Americans will be diagnosed with ALL and 1,440 will die from the disease in 2014. Blincyto is an example of immunotherapy, a treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. Blincyto is the first approved drug that engages the body’s T-cells, a type of white blood cell or lymphocyte, to des ... Read more

Related support groups: Leukemia, Acute Lymphoblastic Leukemia

Obese Children With Leukemia Fared Worse in Study

Posted 27 Oct 2014 by

MONDAY, Oct. 27, 2014 – Obesity may change the way young people react to chemotherapy for acute lymphoblastic leukemia, new research suggests. The study showed that obesity made young people more than twice as likely to have leftover leukemia cells. That puts them at a higher risk of the cancer coming back and of death, the researchers said. The findings could explain why obese young people do worse on initial chemotherapy – called induction therapy – than their peers who aren't obese. "Induction chemotherapy provides a patient's best chance for remission or a cure," principal investigator Dr. Steven Mittelman, of The Saban Research Institute of Children's Hospital Los Angeles, said in a hospital news release. "Our findings indicate that a patient's obesity negatively impacts the ability of chemotherapy to kill leukemia cells, reducing the odds of survival." However, the current ... Read more

Related support groups: Obesity, Acute Lymphoblastic Leukemia

Immune Therapy Induces Remission for Many With a Tough-to-Treat Blood Cancer

Posted 15 Oct 2014 by

WEDNESDAY, Oct. 15, 2014 – An experimental immune-system therapy can often lead to complete remission in leukemia patients who have run out of other options, a new study confirms. Researchers found that 27 of 30 children and adults with advanced acute lymphoblastic leukemia (ALL) went into full remission after receiving genetically tweaked versions of their own immune system cells. "Ninety percent of patients who had no options left went into complete remission. That's amazing," said senior researcher Dr. Stephan Grupp, of Children's Hospital of Philadelphia and the University of Pennsylvania. However, seven patients who went into remission did eventually suffer a relapse, according to the study. The findings, published Oct. 16 in the New England Journal of Medicine, confirm what smaller studies have suggested: The therapy offers hope to people with ALL that has repeatedly eluded ... Read more

Related support groups: Acute Lymphoblastic Leukemia

FDA Approves Purixan (mercaptopurine) Oral Suspension

Posted 29 Apr 2014 by

April 29, 2014 – On April 28, 2014, the U. S. Food and Drug Administration approved an oral suspension of mercaptopurine (Purixan, NOVA Laboratories Limited). Mercaptopurine is a 20 mg/ml oral suspension. Purixan is indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen. Mercaptopurine is an integral component of ALL therapy. Successive clinical trials have demonstrated that mercaptopurine contributes to successful maintenance therapy and improved survival of patients with ALL. Mercaptopurine was originally approved as a 50 mg tablet in 1953, and since this approval has only been commercially available as a 50 mg tablet. Because of the age and weight range of children with ALL, a 50 mg tablet is not ideal. Body surface area dosing and dose adjustments are not easily accomplished with the 50 mg tablet. Tablets are not an ... Read more

Related support groups: Mercaptopurine, Acute Lymphoblastic Leukemia

Experimental Therapy Shows Promise Against Type of Adult Leukemia

Posted 19 Feb 2014 by

WEDNESDAY, Feb. 19, 2014 – An experimental therapy that genetically tweaks the immune system may effectively treat a type of adult leukemia that often has a grim prognosis. Researchers found that of 16 patients with advanced B-cell acute lymphoblastic leukemia (ALL), 88 percent went into remission after being treated with genetically altered versions of their own immune system cells. The findings, reported Feb. 19 in the journal Science Translational Medicine, extend research published last spring on the first five patients to receive the treatment. "First and foremost, we've shown that this isn't a fluke. This is a reliable result," said study senior author Dr. Renier Brentjens, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City. There is still plenty of work to be done, he and other experts cautioned. The treatment, known as T-cell therapy, is not yet approved ... Read more

Related support groups: Acute Lymphoblastic Leukemia

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups


Related Drug Support Groups

methotrexate, Gleevec, Sprycel, mercaptopurine, Adriamycin, imatinib, dasatinib, doxorubicin, Oncaspar, view more... Purinethol, nelarabine, Trexall, Methotrexate LPF Sodium, Iclusig, Folex PFS, Adriamycin RDF, Adriamycin PFS, Erwinaze, Blincyto, Purixan, Marqibo, Arranon, asparaginase erwinia chrysanthemi, blinatumomab, ponatinib, teniposide, clofarabine, Clolar, Vumon, pegaspargase, vincristine liposomal